Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years-Reference-Cited by-同舟云学术

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Published:2021-05 Issue: Volume:149 Page:82-90
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Jacquet Emmanuelle,Kerouani-Lafaye Ghania,Grude Francoise,Goncalves Sergio,Lorence Annie,Turcry Florence,Brunel Liora,Belgodere Laetitia,Monard Adrien^ORCID,Guyader Gaëlle,Boudali Lotfi,Albin Nicolas

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;Ferlay;Int J Canc,2019

2. Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018,2019

3. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study;Arnold;Lancet Oncol,2019

4. Mortality due to cancer treatment delay: systematic review and meta-analysis;Hanna;BMJ,2020

5. Early market access of cancer drugs in the EU;Martinalbo;Ann Oncol,2016

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of expanded access programs for systemic anticancer therapy in an Irish cancer centre;Irish Journal of Medical Science (1971 -);2024-05-28

2. The economic impact of 14 compassionate use programs for medicines in Italy, in the perspective of the National Health Service;Global and Regional Health Technology Assessment;2024-05-21

3. Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs;BioDrugs;2024-04-20

4. Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021;ESMO Open;2024-02

5. Differences in time to patient access to innovative cancer medicines in six European countries;International Journal of Cancer;2023-10-20